Gefitinib may be effective to treat esophageal cancer in some patients
the ONA take:
According to new research published in The Lancet Oncology, gefitinib, a drug already used to treat lung cancer, may be effective to treat esophageal cancer in a small subgroup of patients. In the Cancer Oesophagus Gefitinib study, researchers tested gefitinib in patients with esophageal cancer who had progressed after chemotherapy.
The study showed that gefitinib had minimal impact on most patients and only increased survival rates by a small amount; however, the drug did drastically improve the quality of life, survival duration, and symptom control in about 15% of patients. The main adverse effect was diarrhea.
Russell Petty, PhD, of the University of Aberdeen in Aberdeen, Scotland and senior researcher of the study said that the patients who improved on gefitinib did so within a few weeks of initiating therapy and some patients had disease control for almost 2 years. Dr. Petty notes that not all patients with esophageal cancer should be offered gefitinib and that there is a need for a test to screen whether a patient would improve on gefitinib.
Gefitinib (Iressa), a tyrosine kinase inhibitor, was approved in 2003 by the U.S. Food and Drug Administration to treat advanced EGFR mutation-positive non-small cell lung cancer.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
The University of Aberdeen was involved in a UK wide study to see if the drug gefitinib - already used in lung cancer - could help treat oesophageal cancer.
The Cancer Oesophagus Gefitinib trial was the first study conducted in oesophageal cancer patients whose disease had progressed after chemotherapy.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|